Ligand Pharma (LGND) Announced FDA Expanded Use of Promactao to Include Treatment of Young Children
Tweet Send to a Friend
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announces that the FDA has approved an expanded use for Promacta® (eltrombopag), a Novartis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
